Submission of applications for subsidies under the "Early Detection" sub-program is open until March 2022

03

Jan 2022

The Dutch Organization for Health Research and Development (ZonMw) works to improve disease prevention, healthcare practices, and the health status of the Dutch citizens by stimulating and funding research, development, and implementation of innovative technologies.

The "Early Detection" sub-program is part of the ZonMw prevention program. This sub-program provides subsidies for upscaling screening programs or population screening. The subsidy focuses on knowledge development on the following topics:

  • Information provision and awareness to increase involvement in screening programs among specific target population groups, the interaction between population studies and awareness;
  • Self-screening using innovative techniques;
  • DNA self-tests among citizens;
  • Advantages and disadvantages of the commercial Direct To Consumer (DTC) DNA self-tests for citizens and healthcare providers.

For small projects, a maximum subsidy of €200,000 per project with a maximum duration of 24 months can be applied for. For large projects, a maximum subsidy of €201,000-400,000 and a maximum duration of 24 to 48 months can be applied for. Co-funding from public or private sources is possible but not mandatory. Potential contributions from third parties should amount to a maximum of 50% of the total research budget.

The applications for the subsidy shall be submitted until March 8, 2022.

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

17

Jan 2022

Dutch Healthcare Authority (NZa) has issued a draft release of the DRG package for 2023, including a new procedure code for intermittent pneumatic compression therapy, a new diagnosis code for guidance in early pregnancy after a fertility program, and several new DRGs for pediatric palliative care, lymphovenous anastomosis surgery and light therapy in inflammatory dermatoses.

Read more

11

Jan 2022

In December 2021, NHSX announced that the new elective recovery tech fund would support over 400 innovative digital technologies. The fund has been established to help NHS organizations accelerate the uptake of digitally supported elective care. Up to £250 million has been made available to Integrated Care Systems as a part of a £700 million Targeted Investment Fund intended to speed up elective recovery and tackle waiting lists.

Read more

04

Jan 2022

On December 15, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced that seventeen applications for Innovation Funding of the new forms of care were accepted.

Read more

31

Dec 2021

The French Ministry of Solidarity and Health constantly announces the new experiments initiated under Article 51 of the Social Security Financing Act. These experiments are focused on various topics concerning medical technologies and the organization of care. At the end of December 2021, new experiments were announced which relate to coordinated care of patients with long-term illnesses, telerehabilitation program for patients with COPD, care pathway for patients suffering from lymphedema, surgery for pterygium, and others.

Read more

14

Dec 2021

In early December 2021, NHS Accelerated Access Collaborative announced seven technologies that will be covered by the MedTech Funding Mandate (MTFM) in 2022/23: four for benign prostatic hyperplasia treatment (UroLift, GreenLight XPS, Rezum, and PLASMA system), and three for improving the patient experience during procedures (XprESS multi-sinus dilation system, Thopaz+, and Spectra Optia). Four technologies included in 2021/22 (placental growth factor-based testing, SecurAcath, HeartFlow, and gammaCore) will continue to be supported.

Read more